Related coverage linked through entity extraction aliases.
Jul 03, 2026
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
Apr 18, 2026
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Mar 24, 2026
Precision medicine is transforming healthcare through genetic testing and AI integration, with research showing direct-to-consumer testing identifies unknown health risks and drives medical action. However, reimbursement systems lag behind scientific advances, creating barriers to widespread adoption of personalized treatment approaches.
Mar 12, 2026
The FDA issued reforms on January 11, 2026, loosening chemistry, manufacturing, and control requirements for cell and gene therapy products to advance innovation and accommodate the unique complexity of these treatments.
